Contrast media/contrast agent market 2019-2030 : World Consumption

New Post Public Reply Private Reply Replies (0) Message Board
dorotheapiper
658
The contrast media/contrast agent market report also contains a detailed forecast for the years 2019 – 2030. The forecast is aimed at understanding the Bisphenol Fluorene in various ways to assess the share, size and the growth rate of the overall market worldwide.

Major Players in the contrast media/contrast agent Market
The prominent players in the global contrast media/contrast agent market are GE healthcare, Bayer, Bracco Diagnostics, Guerbet. These players have adopted various strategies like new product launches and product approval from regulatory bodies that has enabled them to acquire a large share in the market. Moreover clinical studies using contrast media and funding for clinical trials for various application has also helped them garner market share. Other prominent players in the market are Lantheus, J.B. Chemicals and Pharmaceuticals, Daiichi Sankyo, Taejoon Pharm, and Jodas among others.

Request Sample: @ https://www.marketindustryreports.com/pdf/71

The continual growth of the contrast media/contrast agent market can be attributed to attributed to increasing number of approvals for contrast agents by regulatory authority, rise in number of public and private diagnostic centers, and rapidly growing global cancer population. The increasing number of research and funding activities for research using contrast agents and their applications provides immense opportunities for companies in the market.
North America to dominate the Market

North America is estimated to account for the largest share of the market during the forecast period. The growth of this region can be accounted owing to rise in FDA approvals, continuously growing economy, and increasing use of contrast media/contrast agent is anticipated to present a lucrative growth scenario for the contrast media/contrast agent market in this region. Moreover, supportive government healthcare regulations and regulation related to contrast media are expected to present an attractive growth prospect for the market in the coming years.

Side Effects, Allergic Reactions, and Adverse Effects Associated With Contrast Agents
Many patient and physician have recorded adverse effect related to contrast media/contrast agent. According to a paper published in Journal of Radiology it was observed that varied levels of residual gadolinium were accumulated in the brain. This may be toxic to patients administrated by gadolinium based contrast. Moreover, patients have suffered from itching delayed allergic reactions, anaphylactic reactions, and cutaneous reactions. Furthermore, FDA has recalled various contrast media/contrast agent products owing to their side effects and new guidelines are placed to curb these problems. These adverse effects, side effects and allergic reaction are restraining the growth of the market to a certain extent.

ASK FOR DISCOUNT @ https://www.marketindustryreports.com/discount/71

Table of Contents

1. INTRODUCTION
1.1. Market Definition
1.2. Market Ecosystem
1.2.1. Market Classification
1.2.2. Geographic Scope
1.2.3. Years Considered for the Study: Historical Years – 2016 & 2017; Base Year – 2018; Forecasted Years – 2019 to 2030
1.3. Currency Used

2. RESEARCH METHODOLOGY
2.1. Research Framework
2.2. Data Collection Technique
2.3. Data Sources
2.3.1. Secondary Sources
2.3.2. Primary Sources
2.4. Market Estimation Methodology
2.4.1. Bottoms Up Approach
2.4.2. Top Down Approach
2.5. Data Validation and Triangulation
2.5.1. Market Forecasting Model
2.5.2. Limitations/Assumptions of the Study
3. ABSTRACT OF THE STUDY
4. MARKET DYNAMICS ASSESMENT
4.1. Overview
4.2. Drivers
4.3. Barriers/Challenges
4.4. Opportunities

Order Full Copy of Report @ https://www.marketindustryreports.com/checkout/71

About Market Industry Reports-
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities.


Contact Us-
502, Sai Radhe, Kennedy Road,
Behind Hotel Sheraton Grand,
Near Pune Station, Pune 411 001
Email: sales@marketindustryreports.com
Phone: +1 347 767 5477 ( US ) | + 91 8956 767 535 ( IN )
Website: https://www.marketindustryreports.com/
Follow Us- LinkedIn | Twitter | Google+ | Face book

Sensivida Medical (SVMT) Stock Research Links

SVMT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 184

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 184

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 295

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 153

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 168

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 132

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading

Top 5 Most Recently Viewed Articles

Telenor Group's Q3 2024 Results: Join Us for Insights

Updated Category News Views 304

Join Telenor Group for a Detailed Overview of Q3 2024 Results Telenor Group invites you to participate in the forthcoming results announcement for the third quarter of 2024. This event is an exciting opportunity to gain crucial insights into the company's performance and strategic direction. Details of the Presentation The presentation is scheduled for a morning session,...

Continue Reading
Azafaros Secures Key Approvals for Phase 3 Trials of Nizubaglustat

Updated Category News Views 322

Azafaros Achieves Critical Milestones in Regulatory Approvals Azafaros B.V. has recently announced significant advancements regarding its lead asset, nizubaglustat, which has garnered orphan drug designation from both United States and European regulatory authorities. This designation is specifically for the treatment of GM1 gangliosidosis, a rare lysosomal storage...

Continue Reading
Refresco's Leadership Changes Set the Stage for Future Growth

Updated Category News Views 373

Refresco's Leadership Changes Set the Stage for Future Growth Refresco, a prominent independent beverage solutions provider, recently announced that its Chief Executive Officer, Hans Roelofs, will be retiring. This transition marks a significant moment not only for Hans but also for the company, which has been under his stewardship for nearly two decades. Hans Roelofs: A...

Continue Reading
How a $1000 Investment in Home Depot Would Have Grown

Updated Category News Views 148

Home Depot: A Strong Investment Choice Home Depot has proven itself as a robust performer in the stock market over the years. With an impressive market capitalization of $379.06 billion, it has outshone the market by approximately 6.8% annually. The average annual return of 19.17% that the company has generated is nothing short of remarkable. This growth exemplifies the...

Continue Reading
AI Stocks Face Market Correction Amid Recovery Clouds

Updated Category News Views 207

The Shift in AI Stock Momentum The exhilarating rally that captivated investors in the spring is now showing signs of fatigue. What we're witnessing is not merely a dip, but a significant reality check across global markets. Japanese indices experienced dramatic declines, with the Nikkei plummeting over 4%—its steepest single-day drop in recent memory. Traders are...

Continue Reading